439 related articles for article (PubMed ID: 23833046)
1. Epidemiology of symptomatic drug-induced long QT syndrome and Torsade de Pointes in Germany.
Sarganas G; Garbe E; Klimpel A; Hering RC; Bronder E; Haverkamp W
Europace; 2014 Jan; 16(1):101-8. PubMed ID: 23833046
[TBL] [Abstract][Full Text] [Related]
2. A case series of drug-induced long QT syndrome and Torsade de Pointes.
Tong KL; Lau YS; Teo WS
Singapore Med J; 2001 Dec; 42(12):566-70. PubMed ID: 11989578
[TBL] [Abstract][Full Text] [Related]
3. Drug-induced torsades de pointes in an underserved urban population. Methadone: is there therapeutic equipoise?
Romero J; Baldinger SH; Goodman-Meza D; Engstrom K; Valencia CR; Golive A; Medrano F; Rangasamy S; Makkiya M; Fisher JD; Gross J; Krumerman A; Kim S; Garcia MJ; Di Biase L; Ferrick KJ
J Interv Card Electrophysiol; 2016 Jan; 45(1):37-45. PubMed ID: 26589717
[TBL] [Abstract][Full Text] [Related]
4. Drug-induced torsades de pointes: a review of the Swedish pharmacovigilance database.
Aström-Lilja C; Odeberg JM; Ekman E; Hägg S
Pharmacoepidemiol Drug Saf; 2008 Jun; 17(6):587-92. PubMed ID: 18449951
[TBL] [Abstract][Full Text] [Related]
5. The morphology of the QT interval predicts torsade de pointes during acquired bradyarrhythmias.
Topilski I; Rogowski O; Rosso R; Justo D; Copperman Y; Glikson M; Belhassen B; Hochenberg M; Viskin S
J Am Coll Cardiol; 2007 Jan; 49(3):320-8. PubMed ID: 17239713
[TBL] [Abstract][Full Text] [Related]
6. Predicting the Unpredictable: Drug-Induced QT Prolongation and Torsades de Pointes.
Schwartz PJ; Woosley RL
J Am Coll Cardiol; 2016 Apr; 67(13):1639-1650. PubMed ID: 27150690
[TBL] [Abstract][Full Text] [Related]
7. Citalopram induced torsade de pointes, a rare life threatening side effect.
Kanjanauthai S; Kanluen T; Chareonthaitawee P
Int J Cardiol; 2008 Dec; 131(1):e33-4. PubMed ID: 17919753
[TBL] [Abstract][Full Text] [Related]
8. Clinical characterization of men with long QT syndrome and torsades de pointes associated with hypogonadism: A review and pharmacovigilance study.
Salem JE; Bretagne M; Lebrun-Vignes B; Waintraub X; Gandjbakhch E; Hidden-Lucet F; Gougis P; Bachelot A; Funck-Brentano C;
Arch Cardiovasc Dis; 2019 Nov; 112(11):699-712. PubMed ID: 31477476
[TBL] [Abstract][Full Text] [Related]
9. Takotsubo cardiomyopathy and QT interval prolongation: who are the patients at risk for torsades de pointes?
Samuelov-Kinori L; Kinori M; Kogan Y; Swartzon M; Shalev H; Guy D; Ferenidou F; Mashav N; Sadeh B; Atzmony L; Kliuk-Ben-Basat O; Steinvil A; Justo D
J Electrocardiol; 2009; 42(4):353-357.e1. PubMed ID: 19261294
[TBL] [Abstract][Full Text] [Related]
10. Cases of drug-induced Torsade de Pointes: a review of Belgian cases in the EudraVigilance database.
Vandael E; Vandenberk B; Vandenberghe J; Willems R; Foulon V
Acta Clin Belg; 2017 Dec; 72(6):385-390. PubMed ID: 28335691
[TBL] [Abstract][Full Text] [Related]
11. Drug-induced long QT syndrome and torsade de pointes.
Morissette P; Hreiche R; Turgeon J
Can J Cardiol; 2005 Aug; 21(10):857-64. PubMed ID: 16107909
[TBL] [Abstract][Full Text] [Related]
12. Incidence of Torsade de Pointes in a tertiary hospital population.
Vandael E; Vandenberk B; Vandenberghe J; Pincé H; Willems R; Foulon V
Int J Cardiol; 2017 Sep; 243():511-515. PubMed ID: 28576628
[TBL] [Abstract][Full Text] [Related]
13. Assessment of drug-induced torsade de pointes risk for hospitalized high-risk patients receiving QT-prolonging agents.
Jardin CG; Putney D; Michaud S
Ann Pharmacother; 2014 Feb; 48(2):196-202. PubMed ID: 24301687
[TBL] [Abstract][Full Text] [Related]
14. Exome sequencing implicates an increased burden of rare potassium channel variants in the risk of drug-induced long QT interval syndrome.
Weeke P; Mosley JD; Hanna D; Delaney JT; Shaffer C; Wells QS; Van Driest S; Karnes JH; Ingram C; Guo Y; Shyr Y; Norris K; Kannankeril PJ; Ramirez AH; Smith JD; Mardis ER; Nickerson D; George AL; Roden DM
J Am Coll Cardiol; 2014 Apr; 63(14):1430-7. PubMed ID: 24561134
[TBL] [Abstract][Full Text] [Related]
15. QT interval prolongation and the risk of torsades de pointes: essentials for clinicians.
Trinkley KE; Page RL; Lien H; Yamanouye K; Tisdale JE
Curr Med Res Opin; 2013 Dec; 29(12):1719-26. PubMed ID: 24020938
[TBL] [Abstract][Full Text] [Related]
16. QT interval prolongation: prevalence, risk factors and pharmacovigilance data among methadone-treated patients in France.
Perrin-Terrin A; Pathak A; Lapeyre-Mestre M
Fundam Clin Pharmacol; 2011 Aug; 25(4):503-10. PubMed ID: 20825488
[TBL] [Abstract][Full Text] [Related]
17. Prevalence of Microvolt T-Wave Alternans in Patients With Long QT Syndrome and Its Association With Torsade de Pointes.
Takasugi N; Goto H; Takasugi M; Verrier RL; Kuwahara T; Kubota T; Toyoshi H; Nakashima T; Kawasaki M; Nishigaki K; Minatoguchi S
Circ Arrhythm Electrophysiol; 2016 Feb; 9(2):e003206. PubMed ID: 26839386
[TBL] [Abstract][Full Text] [Related]
18. Does low-dose droperidol administration increase the risk of drug-induced QT prolongation and torsade de pointes in the general surgical population?
Nuttall GA; Eckerman KM; Jacob KA; Pawlaski EM; Wigersma SK; Marienau ME; Oliver WC; Narr BJ; Ackerman MJ
Anesthesiology; 2007 Oct; 107(4):531-6. PubMed ID: 17893447
[TBL] [Abstract][Full Text] [Related]
19. Giant T-U waves precede torsades de pointes in long QT syndrome: a systematic electrocardiographic analysis in patients with acquired and congenital QT prolongation.
Kirchhof P; Franz MR; Bardai A; Wilde AM
J Am Coll Cardiol; 2009 Jul; 54(2):143-9. PubMed ID: 19573731
[TBL] [Abstract][Full Text] [Related]
20. Predicting torsade de pointes in acquired long QT syndrome: optimal identification of critical QT interval prolongation.
Chiladakis J; Kalogeropoulos A; Zagkli F; Koutsogiannis N; Chouchoulis K; Alexopoulos D
Cardiology; 2012; 122(1):3-11. PubMed ID: 22626988
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
